Novel Therapeutic Approaches with DNA Damage Response Inhibitors for Melanoma Treatment

Targeted therapies against components of the mitogen-activated protein kinase (MAPK) pathway and immunotherapies, which block immune checkpoints, have shown important clinical benefits in melanoma patients. However, most patients develop resistance, with consequent disease relapse. Therefore, there...

Descripción completa

Detalles Bibliográficos
Autores principales: Maresca, Luisa, Stecca, Barbara, Carrassa, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099918/
https://www.ncbi.nlm.nih.gov/pubmed/35563772
http://dx.doi.org/10.3390/cells11091466

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099918/
https://www.ncbi.nlm.nih.gov/pubmed/35563772
http://dx.doi.org/10.3390/cells11091466

Ejemplares similares